Prognostic impact of progesterone receptor status in patients with breast cancer and isolated locoregional recurrence
Authors:
Open Access
- 21 June 2026
- journal article
- Published by Springer Nature in Breast Cancer
- Vol. 33 (5) , 1070-1081
Abstract
Background: The impact of progesterone receptor (PR) status on the prognosis of breast cancer after isolated locoregional recurrence (ILRR) remains unclear. This study assessed the prognostic impact of the PR status of ILRR tumors in patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Methods: The study utilized data from the Japanese National Clinical Database (2004–2015), including 1,625 patients with ER+/HER2- ILRR. All participants were patients aged between 20 and 75 years at diagnosis who underwent curative surgery for ER+/HER2- primary breast cancer. Patients were classified into three groups based on the PR status of primary (p) and recurrent (r) tumors. We compared the overall survival (OS) and breast cancer-specific survival (BCSS) among the three groups using the Kaplan–Meier method with the log-rank test. ER and PR were considered positive if immunohistochemistry staining was positive in > 1% of tumor cells. For the ER expression levels in ILRR tumors, 1–10% were considered as ER-low positive. Results: Patients with PR- ILRR (pPR-/rPR- and pPR+/rPR-) had significantly worse OS and BCSS than those with PR+ ILRR (pPR+/rPR+). Factors associated with worse outcomes included lymph node metastasis, a shorter disease-free interval, ER-low positivity, and no surgery for ILRR tumor. Conclusions: This study highlights PR-negativity in ER+/HER2- ILRR tumors as a poor prognostic factor after ILRR, independent of the PR status of the primary breast cancer, emphasizing the need for tailored treatment strategies.Keywords
This publication has 50 references indexed in Scilit:
- A prediction model for distant metastasis after isolated locoregional recurrence of breast cancerBreast Cancer Research and Treatment, 2023
- Characteristics of female breast cancer in japan: annual report of the National Clinical Database in 2018Breast Cancer, 2022
- TP53 mutations are associated with primary endocrine resistance in luminal early breast cancerCancer Medicine, 2021
- Prognostic significance of receptor expression discordance between primary and recurrent breast cancers: a meta-analysisBreast Cancer Research and Treatment, 2021
- Clinicopathological Characteristics and Breast Cancer–Specific Survival of Patients With Single Hormone Receptor–Positive Breast CancerJAMA Network Open, 2020
- Risk stratification system for groups with a low, intermediate, and high risk of subsequent distant metastasis and death following isolated locoregional recurrence of breast cancerBreast Cancer Research and Treatment, 2019
- Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trialsBreast Cancer Research and Treatment, 2017
- Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic DiseaseClinical Breast Cancer, 2015
- Clinical Outcome of Isolated Locoregional Recurrence in Patients With Breast Cancer According to Their Primary Local TreatmentClinical Breast Cancer, 2014
- A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastasesEuropean Journal of Cancer, 2014